<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1876">
  <stage>Registered</stage>
  <submitdate>7/03/2008</submitdate>
  <approvaldate>7/03/2008</approvaldate>
  <nctid>NCT00636558</nctid>
  <trial_identification>
    <studytitle>Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers</studytitle>
    <scientifictitle>A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PSX-X04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Breast Cancer</healthcondition>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CVA21

Experimental: 1 - IV administration of CVA21 in a dose escalation manner


Treatment: drugs: CVA21
IV infusion, dose escalation of one or two infusions of escalating strength

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses.</outcome>
      <timepoint>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To obtain preliminary efficacy data, determine the time course of viraemia and its elimination post-administration of CVA21</outcome>
      <timepoint>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To characterise the time course of the anti-CVA21 antibody response</outcome>
      <timepoint>Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients who are willing and able to provide written informed consent to participate
             in the study.

          2. Male or female aged 18 years or older.

          3. Stage IV solid tumour disease with the primary tumour being any one of the following
             types - breast, prostate or melanoma.

          4. ICAM-1 with or without DAF-expressing tumour. Patients without archival material for
             testing must agree to a new tumour biopsy.

          5. Absence of circulating antibodies to CVA21 (titre &lt; 1:16).

          6. Patients must have failed or refused standard treatment(s).

          7. Adequate haematological, hepatic and renal function, defined as:

               -  ANC &gt; 1.5 x 10^9/L, platelets &gt; 100 x 10^9/L

               -  Bilirubin &lt; 20Âµmol/L, AST &lt; 2.5 times the upper limit of normal

               -  Calculated creatinine clearance &gt; 30 mL/minute

          8. Adequate immunologic function, defined as:

               -  Serum IgG &gt; 5g/L

               -  T cell subsets within normal limits

          9. Fertile males and females must agree to the use of an adequate form of contraception.
             Hormonal contraceptives should be supplemented with an additional barrier method.
             Negative pregnancy test is required in female patients of child-bearing potential.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Presence or history of Central Nervous System (CNS) malignancy.

          2. Patients must not have received chemotherapy within 4 weeks prior to date of consent.

          3. Performance status &gt; 1 on the Eastern Cooperative Oncology Group (ECOG) scale.

          4. Life expectancy &lt; 6 months.

          5. Pregnancy or breastfeeding.

          6. Primary or secondary immunodeficiency, including immunosuppressive disease, and
             immunosuppressive doses of corticosteroids (e.g. prednisolone &gt; 7.5mg per day) or
             other immunosuppressive medications including cyclosporine, azathioprine, interferons,
             within the past 4 weeks.

          7. Positive serology for HIV, hepatitis B or hepatitis C.

          8. Splenectomy.

          9. Presence of uncontrolled infection.

         10. Presence of unstable neurological disease.

         11. Any uncontrolled medical condition that in the opinion of the Investigator is likely
             to place the patient at unacceptable risk during the study or reduce their ability to
             complete the study

         12. Participation in another study requiring administration of an investigational drug or
             biological agent within the last 4 weeks

         13. Known allergy to treatment medication or its excipients

         14. Any other medical or psychological condition that would preclude participation in the
             study or compromise ability to give informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>8</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Cancer Care Centre, St George Hospital - Kogarah, Sydney</hospital>
    <hospital>Redcliffe Hospital - Redcliffe</hospital>
    <postcode>2217 - Kogarah, Sydney</postcode>
    <postcode>4020 - Redcliffe</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Viralytics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4
      melanoma, prostate and breast cancer. This is a dose escalation, safety study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00636558</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boris Chern, MD</name>
      <address>Redcliffe Hospital, Brisbane, Qld., Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>